96 - What’s Hot in Antifungals? Resistance, Drug Monitoring, and New Agents

Speaker(s)

• 

  David Andes, MD

  Professor
  University of Wisconsin
  Madison, Wisconsin

  Disclosure: sFunga : Consultant (Status: Ongoing), Grant/Research Support (Status: Ongoing)
• SC

  Sharon Chen, PhD

  Director
  Microbiology, Westmead Hospital
  Sydney, Australia

  Disclosure: F2G Ltd : Grant/Research Support (Status: Ongoing)
• 

  Melissa Johnson, PharmD, MHS

  Associate Professor of Medicine
  Duke University Medical Center
  Durham, North Carolina

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Learning Objectives:

• summarize concepts of drug resistance mechanisms to antifungal drugs
• assess the role of therapeutic drug monitoring in the treatment of invasive mycoses
• describe novel antifungal targets and drugs in the pipeline

Presentations:

• 2:45pm – 4:00pm EDT

  New Kids on the Block: Antifungal Drug Pipeline
  David Andes, MD – University of Wisconsin
• 2:45pm – 4:00pm EDT

  Tracking Levels: Therapeutic Drug Monitoring
  Melissa D. Johnson, PharmD, MHS – Duke University Medical Center
• 2:45pm – 4:00pm EDT

  Will the Antifungal Work? Emerging Antifungal Drug Resistance
  Sharon C-A Chen, PhD – Microbiology, Westmead Hospital